Safety and Immunogenicity of a Nipah Virus Vaccine

Completed · Phase 1 · Has a placebo group

Conditions studied: Nipah Virus Infection

In brief

A first-in-human, phase 1 trial is to be conducted in a healthy adult population in the US to assess the safety and immunogenicity of three ascending Nipah vaccine (HeV-sG-V; Hendra virus soluble glycoprotein vaccine) dosages. Different dosing regimens and number of doses will also be explored.

Key facts

Study ID

NCT04199169

Run by

Auro Vaccines LLC

People needed

192

Starts

2020-02-18

Expected to finish

2022-05-06

Last updated by the study team

2022-11-17

Who can join

Age: 18 and older, up to 49. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male or non-pregnant female 18 through 49 years of age at the time of consenting and IP administration.
• Provides written informed consent prior to performance of any study-specific procedure.
• Resides in study site area and is able and willing to adhere to all protocol visits and procedures, including plasmapheresis.
• Healthy, as defined by absence of any clinically significant medical conditions, either acute or chronic, as determined by medical history, physical examination, safety laboratory test results, and clinical assessment of the investigator.
• Female subjects of childbearing potential* must have practiced adequate contraception** for 28 days prior to administration of IP and agree to continue adequate contraception until completion of the plasmapheresis session or Visit 5 (Day 57) for subjects not selected for plasmapheresis.
• Females can be considered not of childbearing potential if they are with current bilateral tubal ligation or occlusion, or post-hysterectomy, or post-bilateral ovariectomy, or post-menopause.
• * Adequate contraception is defined as a contraceptive method with failure rate of less than 1% per year when used consistently and correctly and when applicable, in accordance with the product label, for example:
• Abstinence from penile-vaginal intercourse
• Combined estrogen and progesterone oral contraceptives
• Injectable progestogen
• Implants of etonogestrel or levonorgestrel
• Contraceptive vaginal ring
• Percutaneous contraceptive patches
• Intrauterine device or intrauterine system
• Male condom combined with a vaginal spermicide (foam, gel, film, cream or suppository), and/or progesterone alone oral contraceptive
• Female subjects of childbearing potential must have a negative pregnancy test within 24 hours prior to IP administration.

You may not qualify if…

• Previous immunization with an investigational Nipah or Hendra virus vaccine.
• History of disease known to be caused by Nipah or Hendra virus.
• Travel to Kerala state, India within the previous three years or planned travel to Kerala sate or Bangladesh during the study period.
• Known hypersensitivity to any component of the IPs.
• Known hypersensitivity to citrate or ethylene oxide.
• History of hypersensitivity to any vaccine.
• Administration of any vaccine other than the IP within 28 days prior to IP administration or planned administration through completion of plasmapheresis or Visit 5 (Day 57) for subjects not selected for plasmapheresis.
• Administration of any investigational or non-registered drug within 90 days prior to IP administration or planned administration during the study period.
• Administration of immunoglobulin or any blood product within 90 days prior to IP administration or planned administration during the study period.
• Administration of any long-acting immune-modifying drugs (e.g., infliximab or rituximab) or the chronic administration (defined as more than 14 days) of immunosuppressants within 180 days prior to IP administration or planned administration during the study period (includes systemic corticosteroids at doses equivalent to ≥ 0.5 mg/kg/day of prednisone; topical steroids including inhaled and intranasal steroids are not exclusionary).
• Acute illness or fever (body temperature measured orally ≥ 38°C or 100.4°F) at the time of IP administration (once acute illness/fever is resolved, if appropriate, as per investigator assessment, subject may be screened again).
• History of or evidence for chronic clinically significant (as per investigator assessment) disorder or disease (including, but not limited to immunodeficiency, autoimmunity, bleeding or psychiatric disorder, and pulmonary, cardiovascular, metabolic, neurologic, renal, or hepatic disease).
• Any condition that in the opinion of the investigator might compromise the safety or well-being of the subject or compromise adherence to protocol procedures or interfere with planned safety and immunogenicity assessments.
• History of chronic alcohol consumption or drug abuse that in the opinion of the investigator might compromise adherence to protocol procedures or interfere with planned safety and immunogenicity assessments.
• Blood donation or planned blood donation within 28 days prior to IP administration through 28 days after completion of the plasmapheresis session or Visit 5 (Day 57) for subjects not selected for plasmapheresis.
• Pregnant.
• Body weight < 50 kg.
• Body Mass Index (BMI) ≥ 40 kg/m2.
• Infection with human immunodeficiency virus 1 or 2.
• Infection with hepatitis B or hepatitis C virus.
• The following clinical safety laboratory test results will be considered exclusionary, regardless of assessment of clinical significance:
• Hemoglobin (Male) < 13.3 g/dL Hemoglobin (Female) < 12.8 g/dL Hematocrit > 55% Neutrophil count < 1,500 cells/mm3 Eosinophil count > 600 cells/mm3 Platelet count < 130,000 cells/mm3 Creatinine > 1.4 mg/dL ALT > 1.1 x upper limit of the normal range (ULN)* [* per the site clinical laboratory's reference ranges]

Where it is running

• Cincinnati Children's Hospital Medical Center (CCHMC) — Cincinnati, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.